{Reference Type}: Journal Article
{Title}: Local injection of micro-dose anti-interleukin-17A antibody for palmoplantar pustulosis: A real-world study.
{Author}: Xia R;Liu J;Gao Y;Diao Z;Chen D;Zhou C;Zhang Z;Yin Z;
{Journal}: Clin Immunol
{Volume}: 253
{Issue}: 0
{Year}: 2023 08 9
{Factor}: 10.19
{DOI}: 10.1016/j.clim.2023.109694
{Abstract}: Palmoplantar pustulosis (PPP), a chronic and stubborn skin disease, is mainly confined to the palms or/and soles, making it possible for localized use of therapeutic antibodies. In this real-world prospective cohort study, 8 patients with PPP received palms/soles injections of ixekizumab (0.8 mg in 0.1 ml) every 2 to 8 weeks due to the COVID-19 pandemic. The treatment endpoint was a 75% improvement from baseline in Palmoplantar Pustulosis/Psoriasis Area and Severity Index (PPPASI 75). At week 8, 75%, 50% and 12.5% of 8 patients reached PPPASI 50, PPPASI 75 and PPPASI 90. At week 12, 100%, 75% and 25% of 8 patients reached PPPASI 50, PPPASI 75 and PPPASI 90. This is the first study to evaluate the efficacy and safety of local injection of micro-dose ixekizumab for PPP in real clinical practice. A high proportion of patients rapidly achieved PPPASI 75, and maintained long-term efficacy with satisfactory safety.